Rain Therapeutics Provides Interim Analysis of Ph2 Basket Trial of Milademetan
04 Nov 2022 //
GLOBENEWSWIRE
Rain Therapeutics to Participate in Citi’s 17th Annual BioPharma Conference
31 Aug 2022 //
GLOBENEWSWIRE
Rain Tx Completes Enrollment in PIII MANTRA Trial for Milademetan in Liposarcoma
04 Aug 2022 //
GLOBENEWSWIRE
Rain Therapeutics to Present on Milademetan at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
18 May 2022 //
PRESS RELEASE
Rain Therapeutics Presents Non-Clinical Data on Milademetan in MPM
08 Sep 2021 //
GLOBENEWSWIRE
Daiichi Sankyo Initiates Combination Study of 2 Investgl Agents AML
20 Dec 2018 //
PR NEWSWIRE